BREAKING NEWS

BeyondSpring announces submission of New Drug Application (NDA) to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN).
Read more

PIPELINE OVERVIEW

We have a robust drug development pipeline at various clinical and preclinical stages.

Tap the sections below to expand or download the full pipeline chart.

LAST STAGE

LAST STAGE

INVESTOR INITIATED IO

INVESTOR INITIATED IO

OTHER ONCOLOGY PIPELINE

OTHER ONCOLOGY PIPELINE
Note: 1We own global rights to plinabulin in all countries except China. In China, we own a 57.97% interest in our Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), which owns a 100% interest in plinabulin.